Litcius/Paper detail

Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All

Oliver Lomas, Tarek H. Mouhieddine, Sabrin Tahri, Irene M. Ghobrial

2020Cancers44 citationsDOIOpen Access PDF

Abstract

Monoclonal Gammopathy of Undetermined Significance (MGUS) is considered to be a benign precursor condition that may progress to a lymphoproliferative disease or multiple myeloma. Most patients do not progress to an overt condition, but nevertheless, MGUS is associated with a shortened life expectancy and, in a minority of cases, a number of co-morbid conditions that include an increased fracture risk, renal impairment, peripheral neuropathy, secondary immunodeficiency, and cardiovascular disease. This review aims to consolidate current evidence for the significance of these co-morbidities before considering how best to approach these symptoms and signs, which are often encountered in primary care or within a number of specialties in secondary care.

Topics & Concepts

Monoclonal gammopathy of undetermined significanceMedicineMultiple myelomaAsymptomaticDiseaseImmunodeficiencyIntensive care medicinePathologyInternal medicineImmunologyMonoclonalMonoclonal antibodyAntibodyImmune systemMultiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, OutcomesHematological disorders and diagnostics
Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All | Litcius